About Cadence Pharmaceuticals (NASDAQ:CADX)
Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Cadence Pharmaceuticals (NASDAQ:CADX) Frequently Asked Questions
What is Cadence Pharmaceuticals' stock symbol?
Cadence Pharmaceuticals trades on the NASDAQ under the ticker symbol "CADX."
Who are some of Cadence Pharmaceuticals' key competitors?
Some companies that are related to Cadence Pharmaceuticals include GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHP), Hikma Pharmaceuticals (HIK), BTG (BTG), CoLucid Pharmaceuticals (CLCD), SciClone Pharmaceuticals (SCLN), SkyePharma (SKP), Diurnal Group (DNL), Allergy Therapeutics (AGY), Innocoll (INNL), Aegerion Pharmaceuticals (AEGR), Amryt Pharma (AMYT), N4 Pharma (N4P), Venture Life Group (VLG), SLS International (SLS) and Avanir Pharmaceuticals (AVNR).
Has Cadence Pharmaceuticals been receiving favorable news coverage?
News headlines about CADX stock have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cadence Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.32 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Cadence Pharmaceuticals?
Shares of CADX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Cadence Pharmaceuticals?
Cadence Pharmaceuticals' mailing address is 12481 High Bluff Dr Ste 200, SAN DIEGO, CA 92130-3583, United States. The biopharmaceutical company can be reached via phone at +1-858-4361400.
MarketBeat Community Rating for Cadence Pharmaceuticals (CADX)MarketBeat's community ratings are surveys of what our community members think about Cadence Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cadence Pharmaceuticals (NASDAQ:CADX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Cadence Pharmaceuticals (NASDAQ:CADX) Earnings History and Estimates Chart
Cadence Pharmaceuticals (NASDAQ CADX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/28/2014||Q413||($0.04)||($0.05)||$32.51 million||$33.30 million||View||N/A|
|11/5/2013||Q3 2013||($0.08)||($0.08)||$26.61 million||$28.96 million||View||N/A|
|7/31/2013||Q2 2013||($0.11)||($0.14)||$24.03 million||$24.67 million||View||N/A|
|5/2/2013||Q1 2013||($0.14)||($0.02)||$19.44 million||$23.61 million||View||N/A|
|11/5/2012||Q312||($0.19)||($0.19)||$14.16 million||$13.90 million||View||N/A|
Cadence Pharmaceuticals (NASDAQ:CADX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Cadence Pharmaceuticals (NASDAQ:CADX)
No dividend announcements for this company have been tracked by MarketBeat.com
Cadence Pharmaceuticals (NASDAQ CADX) Insider Trading and Institutional Ownership History
Cadence Pharmaceuticals (NASDAQ CADX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/17/2013||William Larue||CFO||Sell||8,500||$9.12||$77,520.00||5,000|| |
|12/2/2013||Scott Byrd||SVP||Sell||7,812||$9.16||$71,557.92||2,000|| |
|11/18/2013||William Larue||CFO||Sell||36,000||$7.30||$262,800.00||5,000|| |
|7/22/2013||Hazel M Aker||SVP||Sell||6,507||$7.81||$50,819.67|| |
|7/17/2013||William R Larue||CFO||Sell||9,000||$7.26||$65,340.00|| |
|7/15/2013||Hazel M Aker||SVP||Sell||6,508||$7.34||$47,768.72|| |
|6/27/2013||William R Larue||CFO||Sell||9,000||$7.20||$64,800.00|| |
|6/10/2013||Malcolm Lloyd-Smith||SVP||Sell||4,000||$7.44||$29,760.00|| |
|6/7/2013||Scott A Byrd||SVP||Sell||67,115||$7.53||$505,375.95|| |
|3/12/2013||Parters Vii L P Domain||Major Shareholder||Sell||10,464||$5.36||$56,087.04|| |
|2/14/2013||Parters Vii L P Domain||Major Shareholder||Sell||8,714||$5.00||$43,570.00|| |
|2/1/2013||Parters Vii L P Domain||Major Shareholder||Sell||9,769||$4.85||$47,379.65|| |
Cadence Pharmaceuticals (NASDAQ CADX) News Headlines
Cadence Pharmaceuticals (NASDAQ:CADX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cadence Pharmaceuticals (NASDAQ:CADX) Income Statement, Balance Sheet and Cash Flow Statement
Cadence Pharmaceuticals (NASDAQ CADX) Stock Chart for Sunday, March, 18, 2018